The Global Cannabinoid Research Center was founded in 2018 by Mike Robinson, known as the Researcher OG, after years of working directly with patients as a compassion provider and serving as a director at the American Academy of Cannabinoid Medicine. His transition from patient support into research continues to shape the Center’s focus on making cannabinoid science understandable outside academic and professional settings.
As a five-time cancer survivor, Robinson also brings lived experience to questions about illness, symptom management, tolerance, and long-term cannabinoid use. The Center’s educational work includes the endocannabinoid system, tolerance, what Robinson describes as ECS balance, and broader questions about maintaining health while using cannabis.
For many patients, the barrier is not simply finding cannabis. It is making sense of rapidly changing research, conflicting claims, unfamiliar terminology, and products that may be marketed faster than healthcare systems can provide guidance about them.
Scientific findings have limited value to patients if they remain locked behind technical language or cannot be translated into something people can use when making real-world decisions about their health. By turning emerging cannabinoid research into more accessible education, the Global Cannabinoid Research Center helps patients engage more meaningfully with questions about treatment, tolerance, product use, and the endocannabinoid system.
The Global Cannabinoid Research Center advances the Safe Access Award by expanding access to understandable cannabinoid science. Its work helps close the gap between what researchers are learning and what patients need to know to participate more confidently in decisions about their own care.
Website: Global Cannabis Research Center
 |
I’m humbled to be nominated for the 2026 Cannabis Safety Award. I founded the Global Cannabinoid Research Center in 2018 to study plants. It quickly became an immersion into the ECS and a study of people having issues from converted cannabinoids. From tolerance sickness, it’s not easy to address these issues head-on across social media networks. When you’re digging deep with the community, access is such an issue that people drop their guard for safety. It’s so important that industry shifts focus to the patient, not the profit and not the product.” — Mike Robinson |
Support Global Cannabinoid Research Center for the 2026 Safe Access Award.
If you appreciate ASA's work, sign up for alerts and updates, and make a donation to support ASA's vital mission.
Share this page
